Re-evaluation of the carcinogenic significance of hepatitis B virus integration in hepatocarcinogenesisEmerging hepatitis B virus infection in vaccinated populations: a rising concern?Effect of parenteral selenium supplementation in critically ill patients: a systematic review and meta-analysisNew variants and age shift to high fatality groups contribute to severe successive waves in the 2009 influenza pandemic in Taiwan.Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma.Long-term results of a randomized, observation-controlled, phase III trial of adjuvant interferon Alfa-2b in hepatocellular carcinoma after curative resection.Eltrombopag before procedures in patients with cirrhosis and thrombocytopenia.Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.Health-related quality of life in thrombocytopenic patients with chronic hepatitis C with or without cirrhosis in the ENABLE-1 and ENABLE-2 studies.Molecular and phylogenetic analyses suggest an additional hepatitis B virus genotype "I".Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions.Laboratory-based surveillance and molecular epidemiology of influenza virus in Taiwan.Rapid growth of a hepatocellular carcinoma and the driving mutations revealed by cell-population genetic analysis of whole-genome dataEstablishment of a knock-in mouse model with the SLC26A4 c.919-2A>G mutation and characterization of its pathologyAdjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrenceCharacterization of integration patterns and flanking cellular sequences of hepatitis B virus in childhood hepatocellular carcinomas.Evidence for association with hepatocellular carcinoma at the PAPSS1 locus on chromosome 4q25 in a family-based studyCirculating programmed death-1 as a marker for sustained high hepatitis B viral load and risk of hepatocellular carcinoma.Longitudinal change of HBsAg in HBeAg-negative patients with genotype B or C infection.Linifanib versus Sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial.Seroprevalence of Hepatitis E Virus Infection among Swine Farmers and the General Population in Rural TaiwanADAR2-mediated editing of miR-214 and miR-122 precursor and antisense RNA transcripts in liver cancersAge-related immune clearance of hepatitis B virus infection requires the establishment of gut microbiotaDepletion of β-catenin from mature hepatocytes of mice promotes expansion of hepatic progenitor cells and tumor development.Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibitionOncolytic virotherapy for advanced liver tumours.Tumor necrosis factor-alpha blockage therapy impairs hepatitis B viral clearance and enhances T-cell exhaustion in a mouse modelGlobal patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE StudyEpidemiology of HBV infection in Asian blood donors: emphasis on occult HBV infection and the role of NAT.Characterization of severe acute respiratory syndrome coronavirus genomes in Taiwan: molecular epidemiology and genome evolution.Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody.The Hepatitis Viral Status in Patients With Hepatocellular Carcinoma: a Study of 3843 Patients From Taiwan Liver Cancer NetworkAssociations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma.Bortezomib overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance in hepatocellular carcinoma cells in part through the inhibition of the phosphatidylinositol 3-kinase/Akt pathway.Updates on the treatment and outcomes of dual chronic hepatitis C and B virus infection.Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: experts' opinion.Role of microRNAs in hepatitis B virus replication and pathogenesis.Consensus recommendations and review by an International Expert Panel on Interventions in Hepatocellular Carcinoma (EPOIHCC).Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90.Anti-viral treatment and cancer control.
P50
Q21134147-92AF4D01-CC35-4A58-BEDF-D9D818970FC2Q27012663-BD895B85-F483-46C3-9439-13744D166EE3Q27022375-24E73CC2-DD97-46A4-A6EC-09A513DB9D0AQ30224859-3F19D031-C0D3-45E4-A95E-EB3FCCA10FE2Q30479629-B1AE84D2-2A81-4040-BA9C-E7E5BA8F5313Q33398383-39EF5C98-B87F-42B5-A6AF-126A87F1C9C2Q33402924-2AC8057B-013C-4F5C-9302-069004BAF159Q33410939-5A4321C9-977A-4CD8-A1EE-668EF4606836Q33430951-BF1BF8F9-F240-433E-B5DF-2F681D235DA0Q33533304-15E31588-A1A1-4F17-95B2-FDD2DFCA3BC4Q33718958-FFF64EA8-A0F0-408E-B4AB-01D8DD37404BQ33753268-32D8C665-66EC-41B6-991F-C1438CF0CB68Q33951424-1BD6494D-B95B-4EE7-A12E-BC48D0893854Q33979710-6D34F543-45EE-48C0-BD9F-2511291C9EE7Q34093919-7C6495CA-B838-4554-B620-D89A83E33121Q34154219-E932D8C9-E53D-4AA7-B790-95AFAF8C8B65Q34327140-3e5c53d0-4037-c2f2-a2d2-730dbdd8c321Q34576356-B69E1C9B-D3EF-4952-B9D8-9D8218F1D0F1Q34598267-1E49FACE-D4FD-463E-8C5D-CD47EE6AF979Q34786090-DA12F504-994B-486E-BFB4-1A4942288051Q34806688-A1963BEF-98B4-4BF4-AE8F-E48A9FBBB9A0Q35079974-68B6DF2A-E596-4154-856E-28C36EBF5EF1Q35129064-585D2BD0-266A-4FBC-9FA0-004BC331C2C6Q35546735-B7B37BDC-F851-4E4C-8013-0B0438973C18Q35740334-21AD7166-526A-4E08-9776-13685111F1A3Q35832074-A8A19412-0113-4A2D-8B4B-2E3B168890E9Q36302689-E1BCCFEA-52CC-4DBC-8981-6503B930F5C6Q36404761-926596B0-A643-4975-B354-8F3169739EC1Q36532437-3FD01BFA-F414-4328-8BF6-CCBD31979B70Q36602760-43FEE081-7C0A-421D-8CD7-2EE40C0E314FQ36629288-2EFC531D-CAF3-41EB-930B-D49CFF2D4809Q36822340-0c6c8292-4248-958f-e069-2b9fb9d55360Q36841560-45166E03-E905-46B6-9D00-E316C67A68D0Q37160844-3D4A9CB8-0E54-4EEC-9473-8EE912745C5BQ37654521-0976B101-0569-46FE-AF94-74B8F58BE32DQ37765927-3E2EE56B-15AC-4194-9212-66A938F26125Q37874764-4DED495B-C12F-4E90-915A-8D7C320CA469Q38075142-C934A8CA-F193-4E14-A8A4-27F997FFE53BQ38101443-77B72C09-0A29-451B-8DB3-89A26E2FF7F0Q38134557-A7175AA6-1703-487E-B9B9-2C284B3C1438
P50
description
hulumtues
@sq
onderzoeker uit Taiwan
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Pei-Jer Chen
@ast
Pei-Jer Chen
@en
Pei-Jer Chen
@es
Pei-Jer Chen
@nl
Pei-Jer Chen
@sl
陳培哲
@zh
type
label
Pei-Jer Chen
@ast
Pei-Jer Chen
@en
Pei-Jer Chen
@es
Pei-Jer Chen
@nl
Pei-Jer Chen
@sl
陳培哲
@zh
prefLabel
Pei-Jer Chen
@ast
Pei-Jer Chen
@en
Pei-Jer Chen
@es
Pei-Jer Chen
@nl
Pei-Jer Chen
@sl
陳培哲
@zh
P1048
P106
P1153
7408354514
P2038
Pei-Jer_Chen
P21
P214
35146822345407382251
P2456
P27
P31
P496
0000-0001-8316-3785
P569
1955-01-01T00:00:00Z
P7859
viaf-35146822345407382251